Patients incidentally exposed to any type of beta-blocker (i.e., cardioselective beta-blocker or wide spectrum beta-blocker) had a significantly lower intra-tumor blood vessel density, as assessed by CD34 staining. This evidence concerns the gene CD34 and neoplasm.